U.S. PHARMACOPEIA

Search USP29  
Neomycin and Polymyxin B Sulfates and Lidocaine Cream
» Neomycin and Polymyxin B Sulfates and Lidocaine Cream contains the equivalent of not less than 90.0 percent and not more than 130.0 percent of the labeled amounts of neomycin and polymyxin B, and not less than 90.0 percent and not more than 110.0 percent of the labeled amount of lidocaine (C14H22N2O).
Packaging and storage— Preserve in well-closed containers, preferably at controlled room temperature.
Identification—
A: It meets the requirements under Thin-Layer Chromatographic Identification Test 201BNP.
B: The retention time of the major peak for lidocaine in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay for lidocaine.
Minimum fill 755: meets the requirements.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Assay for neomycin— Proceed with Cream as directed in the Assay for neomycin under Neomycin and Polymyxin B Sulfates Cream.
Assay for polymyxin B— Proceed with Cream as directed in the Assay for polymyxin B under Neomycin and Polymyxin B Sulfates Cream.
Assay for lidocaine—
Mobile phase, Standard preparation, and Chromatographic system— Proceed as directed in the Assay for lidocaine under Neomycin and Polymyxin B Sulfates, Bacitracin, and Lidocaine Ointment.
Assay preparation— Using Cream, proceed as directed for the Assay preparation in the Assay for lidocaine under Neomycin and Polymyxin B Sulfates, Bacitracin, and Lidocaine Ointment.
Procedure— Proceed as directed for Procedure in the Assay for lidocaine under Neomycin and Polymyxin B Sulfates, Bacitracin, and Lidocaine Ointment. Calculate the quantity, in mg, of lidocaine (C14H22N2O) in the portion of Cream taken by the formula:
100C(rU / rS),
in which C is the concentration, in mg per mL, of USP Lidocaine RS in the Standard preparation; and rU and rS are the lidocaine peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Staff Liaison : Brian D. Gilbert, Ph.D., Scientist
Expert Committee : (MDANT05) Monograph Development-Antibiotics
USP29–NF24 Page 1511
Pharmacopeial Forum : Volume No. 28(4) Page 1164
Phone Number : 1-301-816-8223